Research has shown that patients treated with programmed cell death protein 1 (PD- 1) inhibitors have a 12.0% to 13.7% incidence of irAEs, with colitis occurring at a rate of 0.7% to 1.6%. This evidence concerns the gene RPL17 and colitis.